Étiquette : cannabidiol

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses, Will Lawn et al., 2016

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Will Lawn, Tom P. Freeman, Rebecca A. Pope, Alyssa Joye, Lisa Harvey, Chandni Hindocha, Claire Mokrysz, Abigail Moss, Matthew B. Wall, Michael A.P. Bloomfield, Ravi K. Das, Celia J.A. Morgan, David J. Nutt, H. Valerie Curran Psychopharmacology, 2016, 233, 3537–3552 Doi : 10.1007/s00213-016-4383-x   Abstract Rationale : Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and [...]

Lire la suite

Cannabinoid receptor expression in nonsmall cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelialmesenchymal transition in vitro, Lara Milian et al., 2020

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial mesenchymal transition in vitro Lara Milian, Manuel Mata, Javier Alcacer, Marıa Oliver, Marıa Sancho-Tello, Jose Javier Martın de Llano, Carlos Camps, Jose Galbis, Julian Carretero, Carmen Carda PLoS ONE, 2020, 15, (2): e0228909. Doi : 10.1371/journal.pone.0228909   Abstract Background/Objective : Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydro-cannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD [...]

Lire la suite

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression, Clarissa Laczkovics et al., 2020

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]

Lire la suite

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species, Faith Borgan et al., 2019

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species Faith Borgan, Katherine Beck, Emma Butler, Robert McCutcheon, Mattia Veronese, Anthony Vernon, Oliver D. Howes Psychopharmacology, 2019 Doi : 10.1007/s00213-019-05283-3   Abstract Rationale : While cannabis-based medicinal products have been shown to be effective for numerous neurological and psychiatric disorders, the evidence base regarding their adverse cognitive effects is poorly understood. The cannabinoid 1 receptor modulates memory performance via intracellular and extracellular mechanisms that alter synaptic transmission and plasticity. While previous literature has consistently shown that chronic cannabis users exhibitmarked cognitive impairments,mixed findings have been reported in the context [...]

Lire la suite

Species-specific susceptibility to cannabisinduced convulsions, Benjamin J Whalley et al., 2018

Species-specific susceptibility to cannabis-induced convulsions Benjamin J Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A Gray, C Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M Williams and Gary J Stephens British Journal of Pharmacology, 2018, 1-18. Doi : 10.1111/bph.14165   BACKGROUND AND PURPOSE Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid [...]

Lire la suite

Cannabis in Chinese Medicine : Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids ?, E. Joseph Brand and Zhongzhen Zhao

Cannabis in Chinese Medicine : Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids? E. Joseph Brand and Zhongzhen Zhao Frontiers in Pharmacology, 2017, vol 8, Article 108, 1-11. doi : 10.3389/fphar.2017.00108   Cannabis sativa L. (Cannabaceae) has a long history of utilization as a fiber and seed crop in China, and its achenes (“seeds”) as well as other plant parts have been recorded in Chinese medical texts for nearly 2000 years. While the primary applications of cannabis in Chinese medicine center around the use of the achenes, ancient indications for the female inflorescence, and other plant parts include conditions such as pain [...]

Lire la suite

European Commission proposes unified EU vote on WHO cannabis scheduling recommendations, Alfredo Pascual, Marijuana Business Daily, 15 janvier 2020

European Commission proposes unified EU vote on WHO cannabis scheduling recommendations Published January 15, 2020 | By Alfredo Pascual https://mjbizdaily.com/european-commission-proposes-unified-eu-vote-on-who-cannabis-scheduling-recommendations/?utm_medium=email&utm_source=newsletter&utm_campaign=INTL_20200115_NEWS_Weekly   In advance of the March session of the United Nations Commission on Narcotic Drugs (CND), the European Union’s executive branch has proposed that EU member nations vote in favor of three of the six World Health Organization (WHO) cannabis scheduling recommendations. The European Commission “Proposal for a Council Decision” is meaningful because – if adopted by the Council of Europe – the EU countries would vote as a block at the CND session in Vienna and the three motions [...]

Lire la suite

Bibliographie : Cannabidiol (CBD), Docteur Christian SUEUR, GRECC, février 2020.

Bibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, février 2020.     voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives

Lire la suite

The therapeutic role of Cannabidiol in mental health : a systematic review, Khan R. at al., 2020

The therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y   Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]

Lire la suite

Le cannabidiol, un agent thérapeutique prometteur ?, Benjamin Rolland et al., 2019

Le cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6.   Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]

Lire la suite